×
About 4,468 results

ALLMedicine™ Hemophilia A Center

Research & Reviews  1,364 results

Drug Use Investigation of Kovaltry in Hemophilia A Patients
https://clinicaltrials.gov/ct2/show/NCT02941783

May 19th, 2022 - This company-sponsored study is a single-arm, prospective, observational study in hemophilia A patients administered Kovaltry. 200 cases will be planned to be registered as safety analysis set in three-year period. Within 200 cases, 50 cases less ...

Study to Learn More About the Safety of Drug Jivi Over a Long Period of Time in Previously Treated Patients With Hemophilia A (Bleeding Disorder Resulting From a Lack of FVIII) Who Are Receiving Ji...
https://clinicaltrials.gov/ct2/show/NCT04461639

May 19th, 2022 - In this observational study researchers want to learn more about the safety of drug Jivi over a long period of time. Jivi (generic name: Damoctocog alfa pegol) is an approved blood clotting Factor VIII (FVIII) medication for the treatment of hemop...

Prophylaxis Regimen for Hemophilia A Patients
https://clinicaltrials.gov/ct2/show/NCT05036278

May 19th, 2022 - Researchers are looking for a better way to treat people who have hemophilia A. Hemophilia A is a genetic bleeding disorder that is caused by the lack of a protein in the blood called "clotting factor 8" (FVIII). FVIII is naturally found in the bl...

Age-stratified adeno-associated virus serotype 3 neutralizing and total antibody preval...
https://doi.org/10.1002/jmv.27859
Journal of Medical Virology; Daniel HD, Kumar S et. al.

May 17th, 2022 - Gene therapy using adeno-associated virus (AAV) vector offers a new treatment option for individuals with monogenetic disorders. The major bottleneck is the presence of pre-existing anti-AAV antibodies, which impacts its use. Even very low titers ...

see more →

Guidelines  1 results

International recommendations on the diagnosis and treatment of patients with acquired ...
https://doi.org/10.3324/haematol.2008.001743
Haematologica Huth-Kühne A, Baudo F et. al.

Apr 2nd, 2009 - Acquired hemophilia A (AHA) is a rare bleeding disorder characterized by autoantibodies directed against circulating coagulation factor (F) VIII. Typically, patients with no prior history of a bleeding disorder present with spontaneous bleeding an...

see more →

Drugs  59 results see all →

Clinicaltrials.gov  121 results

Drug Use Investigation of Kovaltry in Hemophilia A Patients
https://clinicaltrials.gov/ct2/show/NCT02941783

May 19th, 2022 - This company-sponsored study is a single-arm, prospective, observational study in hemophilia A patients administered Kovaltry. 200 cases will be planned to be registered as safety analysis set in three-year period. Within 200 cases, 50 cases less ...

Study to Learn More About the Safety of Drug Jivi Over a Long Period of Time in Previously Treated Patients With Hemophilia A (Bleeding Disorder Resulting From a Lack of FVIII) Who Are Receiving Ji...
https://clinicaltrials.gov/ct2/show/NCT04461639

May 19th, 2022 - In this observational study researchers want to learn more about the safety of drug Jivi over a long period of time. Jivi (generic name: Damoctocog alfa pegol) is an approved blood clotting Factor VIII (FVIII) medication for the treatment of hemop...

Prophylaxis Regimen for Hemophilia A Patients
https://clinicaltrials.gov/ct2/show/NCT05036278

May 19th, 2022 - Researchers are looking for a better way to treat people who have hemophilia A. Hemophilia A is a genetic bleeding disorder that is caused by the lack of a protein in the blood called "clotting factor 8" (FVIII). FVIII is naturally found in the bl...

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
https://clinicaltrials.gov/ct2/show/NCT05145127

May 17th, 2022 - Study B7841007 is an open-label extension study to assess the long-term safety, tolerability, and efficacy of prophylaxis treatment with marstacimab in participants who did not require "Early Termination" from the Phase 3 Study B7841005. Approxima...

Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A
https://clinicaltrials.gov/ct2/show/NCT03932201

May 16th, 2022 - The aim of the HEM-POWR study is to understand better how Damoctocog alfa pegol (Jivi) is used to treat people with Hemophilia A in day-to-day life, how well the treatment is tolerated and how satisfied patients and physicians are with the treatment.

see more →

News  240 results

‘Time Is Blood’: Researchers Devise Shortcut to AHA Diagnosis
https://www.medscape.com/viewarticle/972442

Apr 20th, 2022 - Because they have detected sluggishness in hospital diagnoses, researchers have developed an algorithm to help clinicians determine whether patients have acquired hemophilia A (AHA), a rare bleeding disorder that mainly affects elderly men with me...

Gene Therapy Impresses in Severe Hemophilia A
https://www.medpagetoday.com/hematologyoncology/hemophilia/97695

Mar 16th, 2022 - In men with severe hemophilia A, a single infusion of valoctocogene roxaparvovec significantly increased factor VIII activity and reduced annualized rates of factor VIII concentrate use and bleeding, a phase III study found. Among 132 HIV-negative...

Gene Therapy for Hemophilia A 'Transforming and Liberating'
https://www.medscape.com/viewarticle/970418

Mar 16th, 2022 - A form of gene therapy has shown significant benefit in men with a severe form of the bleeding disorder hemophilia A. Significant results were seen 1 year after receiving a single intravenous infusion of valoctocogene roxaparvovec (AAV5-hFVIII-SQ)...

Post–COVID Vaccine AHA Cases Raise Eyebrows in Italy
https://www.medscape.com/viewarticle/968826

Feb 18th, 2022 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Four cases of acquired hemophilia A (AHA) identified after SARS-CoV-2 immunizations in a province in northern Italy caught the attention of resear...

Post–COVID vaccine AHA cases raise eyebrows in Italy
https://www.mdedge.com/hematology-oncology/article/251919/bleeding-disorders/post-covid-vaccine-aha-cases-raise-eyebrows
Sharon Worcester

Feb 17th, 2022 - Four cases of acquired hemophilia A (AHA) identified after SARS-CoV-2 immunizations in a province in northern Italy caught the attention of researchers, who stressed that the cases are “unusual,” but not necessarily caused by vaccination. “The ove.

see more →

Patient Education  2 results see all →